| Institution | PI Name | Title |
|---|
| Adenosine Therapeutics, LLC | Shannon Williams | Safety of A2A Adenosine Agonist for Treatment of Sepsis |
| AFG Biosolutions, Inc. | Kenneth Alibek | Nisin as a decontaminant for B. anthracis spores on human skin |
| Akonni Biosystems, Inc. | Charles Daitch | Microfluidic Controlled Gel-Drop Microarrays for Biothreat Diagnostic Devices |
| Alnylam Pharmaceuticals | Antonin Defougerolles | siRNA Intervention Strategies for Influenza Infection |
| Alpha Universe, LLC | Alexey Zdanovsky | Development of novel proteins as a defence against potential biothreat agents |
| Atom Sciences, Inc. | Richard Hurt | Bioagent Characterization by Iterative Extension |
| Autoimmune Technologies, LLC | Robert Garry | Peptide drugs against influenza virus |
| Avant Immunotherapeutics, Inc. | Sims Kochi | Development and cGMP Manufacture of a Vitrified Typhoid Vaccine |
| Avidbiotics Corporation | David William Martin | Host Range Diversity of Bacteriophage for Y. pestis |
| Biothera | Myra Patchen | Oral beta-glucan treats hematopoietic injury resulting from acute radiation expos |
| Cellerant Therapeutics, Inc. | Ramkumar Mandalam | Application of Expanded Myeloid Progenitors for Infection (Phase II) |
| Cyto Pulse Sciences, Inc. | Alan King | DNA Vaccine Delivery System for Biodefense with dengue |
| DMX, Inc. | Hao Shen | New attenuated anthrax vaccine |
| Dor Biopharma, Inc. | Robert Newton Brey | Development of a mucosally administered trivalent serotype A,B, E botulinum vaccine |
| EIC Laboratories, Inc. | R. David Rauh | Reagentless Immunosensors Based on Biofunctionalized Nanotubes |
| Endacea, Inc. | Constance Vance | A Novel Treatment in a Bioterrorism Model of Pneumonic Plague Targets A1 ARs |
| Functional Genetics, Inc. | Roxanne Duan | Development of Therapeutic Agents Against Influenza by Targeting Host Factors |
| Gene Therapy Systems, Inc. | Alan Greener | Screening Complete TB Proteome for Protective Antigens |
| Genomics USA, Inc. | Krishna Jayaraman | Population Scale HLA Typing for Homeland Defense |
| Genvec, Inc. | C. Richter King | Novel Adenovirus Vectors for Biodefense Vaccines |
| Hawaii Biotech, Inc. | Sherri Millis | Structure Based Design of Dengue Virus Fusion Inhibitors |
| Hawaii Biotech, Inc. | Sherri Millis | Discovery of West Nile Virus Protease Inhibitors |
| Hawaii Biotech, Inc. | Sean O'Malley | Optimization of Small Molecule Botulinum Neurotoxin Inhibitors |
| IDX Labs, Inc. | Eric Houpt | Real-time PCR diagnostic kit for Giardia and Cryptosporidium |
| Inbios International, Inc. | Antonio Campos-Neto | Antigen Detection Assay for Tuberculosis |
| Inbios International, Inc. | William John Morrow | Development of rapid detection tests for Brucella species |
| Indevr, LLC | Matthew Ferris | Monitoring System For Vector-Based Influenza Vaccine |
| Innovative Surface Technologies, LLC | Kristin Taton | Multianalyte Nanomagnetic Biosensor Array for Pathogen Detection |
| Integral Molecular | Tiffani Greene | SMART Arrays for Pathogen Detection |
| Intrinsic Bioprobes, Inc. | Eric Niederkofler | Mass Spectrometry Assays for Biodefense |
| Investigen, Inc. | Peter Dailey | Easy, fast, point of care nucleic acid based detection of pulmonary tuberculosis |
| Inviragen, LLC | Dan Stinchcomb | Mucosal modified vaccinia Ankara-based plaque vaccines |
| Juvaris Biotherapeutics, Inc. | Jeff Fairman | Lipid/DNA/Antigen Complexes for Influenza A Viral Vaccination |
| Juvaris Biotherapeutics, Inc. | Jeff Fairman | Innate Immune Stimulation as a Pathogen Countermeasure |
| L2 Diagnostics, LLC | Karen Anthony | Small Molecule Alanine Racemase Inhibitors as Novel Therapeutics for Tuberculosis |
| L2 Diagnostics, LLC | Michel Ledizet | Antivirals Targeting Flavivirus Envelope Proteins |
| L2 Diagnostics, LLC | Yorgo Modis | Broad-Spectrum Therapeutic Human Antibodies for Dengue Virus Infections |
| Lynntech, Inc. | Adrian Denvir | Electrochemical Method for Viable Pathogen Detection |
| Lynntech, Inc. | J. Tim Wharton | An Integrated Optical DNA Detector for Portable PCR |
| Lynntech, Inc. | Season Wong | A Nanocrystal-Based Device for Point-of-Care Molecular Differential Diagnostics |
| Maxthera, Inc. | Ania Knap | New Broad-Acting Cell Wall Antibiotics for Biodefense |
| Maxygen, Inc. | Robert Gerald Whalen | Vaccines for Eastern and Western Equine Encephalitis Viruses |
| Microbiotix, Inc. | Arnab Basu | Identification of Ebola Virus Entry Inhibitors |
| Microbiotix, Inc. | Michelle Butler | Development of Inhibitors of Mycobacterium Tuberculosis DNA Replication |
| Microbiotix, Inc. | Donald Moir | Discovery of B. pseudomallei therapeutics for Biodefense |
| Midi, Inc. | Myron Sasser | Rapid Susceptibility Testing of MDR M. tuberculosis- Phase II |
| Molecular Targeting Technology, Inc. | Matthias Johannes Schnell | A novel rhabdovirus-based anthrax vaccine |
| Novobiotic Pharmaceuticals, LLC | Losee Lucy Ling | Developing Novel Antibiotics Against Yersinia pestis |
| Physical Optics Corporation | Gregory Zeltser | Microfluidic Refractometric Biosensor |
| Pinnacle Pharmaceuticals | Larisa Dedkova | Anti-infection Agents that Target Protein Synthesis |
| Planet Biotechnology, Inc. | Keith Wycoff | Botulinum Toxin Plantibodies |
| Planet Biotechnology, Inc. | Keith Wycoff | Novel Therapy for Pulmonary Anthrax |
| Platypus Technologies, LLC | Barbara Israel | Biophotonic detection of WNV Abs from Multiple Species |
| Polymedix, Inc. | Richard Scott | Therapeutic Development of Antimicrobial Biomimetics |
| Promiliad Biopharma, Inc. | Dennis Wright | Potent and selective DHFR inhibitors for treating Cryptosporidiosis |
| Prothera Biologics, LLC | Steven Opal | Role of Inter-alpha Inhibitors in Anthrax Intoxication |
| RX3 Pharmaceuticals, Inc. | John Finn | Novel Antibacterial Designed Multiple-Target Ligands |
| RX3 Pharmaceuticals, Inc. | Mark Alan Stidham | Novel Bacterial Cell Wall Biosynthesis Inhibitors for Biodefense Therapeutics |
| Scarab Genomics, LLC | Frederick Blattner | Clean-Genome vaccines against biodefense agents |
| Sequella, Inc. | Venkata Reddy | Novel mycobacterial translocase I inhibitors--a new class of anti-TB drugs |
| Siga Technologies, Inc. | Sean Amberg | Antiviral Drugs for Lassa Fever Virus |
| Siga Technologies, Inc. | Dennis Hruby | Bacterial Commensal Vector Delivery/Smallpox Vaccine |
| Siga Technologies, Inc. | Robert Jordan | Small Molecule Inhibitors of Smallpox Virus Replication |
| Syntiron, LLC | Laura Wonderling | Salmonella vaccination with iron-regulated membrane proteins |
| Techlab, Inc. | Joel Herbein | New Rapid Diagnostic Tests for Amebiasis |
| Tengen Biomedical Co. | Xiaowu Pang | Development of Pseudoinfectious VLP as Novel JEV Vaccine |
| TSRL, Inc. | Phillip Kish | Bile acid conjugates to improve the oral bioavailability of anti-influenza drugs |
| Vaxin, Inc. | De-Chu Christopher Tang | In-ovo vaccination/avian influenza/bird/human |
| Zuchem, Inc. | David Dodds | Synthesis and Testing of Neoglycoside Glycopeptide Prototypes |